NCT03260504View on ClinicalTrials.gov

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions
Advanced Clear Cell Renal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell CancerMetastatic Clear Cell Renal Cell Carcinoma
Interventions
BIOLOGICAL

Aldesleukin

Given SC or IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Prometheus Laboratories
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Prometheus Laboratories

INDUSTRY

lead

University of Washington

OTHER

NCT03260504 - Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter